India Infectious Disease Therapeutics Market Analysis

India Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Indian infectious disease therapeutics market will reach a value of $3.84 Bn from $2.18 Bn in 2022, growing at a CAGR of 7.4% during 2022-2030.

India is a lower middle-income, developing country located in Southern Asia bordering the Arabian Sea and the Bay of Bengal. According to the World Factbook, India is extremely vulnerable to infectious diseases. Food or waterborne infections include bacterial diarrhoea, hepatitis A and E, and typhoid fever. Two vector-borne diseases are dengue fever, Crimean-Congo haemorrhagic fever, Japanese encephalitis, and malaria. Leptospirosis and rabies are two other infectious diseases unique to India.

The Indian government has launched a number of programmes and policies to promote access to infectious illness treatment. The National Vector Borne Disease Reduce Programme is one such initiative that tries to control the spread of vector-borne diseases such as malaria, dengue fever, and chikungunya. According to a report by the Indian Brand Equity Foundation, the Indian pharmaceutical market is expected to be worth around US$41 Bn in 2020, with anti-infective medications accounting for a significant portion of that figure. India's government spends 3% of its GDP on healthcare.

Market Dynamics

Market Growth Drivers Analysis

India is also a major manufacturer of vaccinations, including polio, measles, and rotavirus vaccines. The Serum Institute of India is the world's largest vaccine factory, generating more than 1.5 Bn doses of vaccines each year. In recent years, India has also worked to address the issue of antimicrobial resistance (AMR), which has become a global concern. Infectious disorders such as tuberculosis, malaria, dengue fever, and HIV/AIDS are prevalent in India. In India, infectious illness medicines have been a key focus of research and development. The Indian government has established a number of programmes to promote antibiotic stewardship and to stimulate the discovery of novel antibiotics and alternative treatments. India has a massive workforce and population (almost half of the population is under the age of 25). These aspects could boost India's infectious disease therapeutics market.

Market Restraints

Developing new pharmaceuticals and therapies necessitates adhering to regulatory rules established by organisations such as India's Central Drugs Standard Control Organization (CDSCO). These requirements can be complicated and time-consuming, resulting in delays and higher expenses. Poverty, inequality, and informality are pervasive in India. Infectious disorders such as tuberculosis, malaria, and dengue fever are prevalent in India. This heavy load can make developing effective therapies and conducting clinical trials difficult. These factors may deter new entrants into the Indian infectious disease therapeutics market.

Competitive Landscape

Key Players

• Serum Institute of India - Serum Institute of India is a leading Indian biotech company that develops and manufactures a range of vaccines, including those for infectious diseases such as polio, measles, and rubella
• Bharat Biotech - Bharat Biotech is an Indian biotechnology company that develops and manufactures vaccines and immunotherapies for infectious diseases such as hepatitis B, polio, and influenza
• Cadila Healthcare - Cadila Healthcare is an Indian pharmaceutical company that develops and manufactures a range of therapeutics, including antibiotics and antivirals
• Lupin Limited - Lupin Limited is an Indian pharmaceutical company that develops and manufactures a range of generic drugs, including those for infectious diseases such as HIV/AIDS and tuberculosis
• Sun Pharmaceutical Industries - Sun Pharmaceutical Industries is an Indian multinational pharmaceutical company that develops and manufactures a range of therapeutics, including antivirals and antibiotics

Recent Notable Updates

January 2023: Sun Pharmaceutical announced the acquisition of three brands from Aksigen Hospital Care, a Mumbai-based research-driven healthcare business with over two decades of experience in the healthcare field: Disperzyme, Disperzyme-CD, and Phlogam. The Drugs Controller General of India ("DCGI") has approved all of the brands for postoperative inflammation in patients having minor surgery and dental treatments.

December 2022: Cadila Pharmaceuticals has signed an Investment Intention Form (IIF) with the Government of Odisha to establish a pharmaceutical formulation manufacturing unit under the newly launched Industrial Policy 2022 of the Odisha government. With an initial investment of Rs 100 crores, the proposed green field pharmaceutical formulations manufacturing complex in Malipada, Bhubaneswar, is expected to be one of the largest pharma manufacturing units in the region. The Odisha government would expedite clearances to aid in the establishment of the aforementioned project.

Healthcare Policies and Reimbursement Scenarios

The Central Drugs Standard Control Organization (CDSCO), a branch of the Ministry of Health and Family Welfare, regulates infectious disease medicines in India. The CDSCO is in charge of ensuring the safety, effectiveness, and high quality of all medicines and medical equipment, particularly those used to treat infectious diseases. In addition to the CDSCO, other regulatory bodies in India that may be involved in the regulation of infectious disease therapeutics include the Indian Council of Medical Research (ICMR), which provides guidance on the use of new treatments within the healthcare system, and the National Health Systems Resource Centre (NHSRC), which provides technical assistance to the Ministry of Health and Family Welfare.

In India, the funding of infectious disease medicines is managed by a combination of governmental and private health insurance providers, such as the Aayushman Bharat scheme. These therapies are either partially or completely covered by insurance, depending on the patient's insurance coverage and the type of treatment. In India, the reimbursement procedure is tier-based, with different levels of coverage depending on the type of insurance coverage and the type of treatment sought. Treatments for life-threatening infectious diseases like HIV or tuberculosis, for example, are often covered at a higher rate than treatments for less serious infections. Treatment must be approved by the Drugs Controller General of India (DCGI) before it may be reimbursed.